Actively Recruiting
Evaluating Once-Weekly Berobenatide Injections for Adults With Knee Osteoarthritis and Overweight or Obesity, With or Without Type 2 Diabetes
Led by Pfizer · Updated on 2026-11-04
756
Participants Needed
4
Research Sites
10 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating berobenatide PF-08653944 for treating knee osteoarthritis in adults who are overweight or obese, with or without type 2 diabetes. This Phase 3 clinical trial aims to learn about the safety and effects of berobenatide over 52 weeks, comparing it with a placebo regarding knee pain, physical function, and body weight. The study involves adults diagnosed with knee osteoarthritis and meeting specific criteria for body mass index and glycemic control. Participants receive either berobenatide or a placebo as a subcutaneous injection once weekly. The study includes multiple groups receiving berobenatide or placebo in a randomized, double-blind, parallel design. Treatment continues for 52 weeks, during which various assessments such as knee pain evaluation, physical function questionnaires, and body measurements are conducted. Throughout the trial, participants undergo blood tests and complete questionnaires to assess knee pain and physical function. Researchers measure changes in pain using the Western Ontario and McMaster Universities Osteoarthritis Index WOMAC pain subscale and monitor body weight. Safety is also tracked through adverse event reporting and laboratory tests. The total participation time for each individual is about one year, including all assessments and monitoring.
CONDITIONS
Brief Title
A Study to Learn About Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Overweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)
Research Team
P
Pfizer CT.gov Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here